Regeneron Pharmaceuticals Inc (REGN)

Debt-to-equity ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	1,982,900	1,982,600	1,982,200	1,981,800	1,981,400	1,981,100	1,980,700	1,980,400	1,980,000	1,979,600	1,979,200	1,978,900	1,978,500	1,978,300	—	—	0	—	—	—
Total stockholders’ equity	US$ in thousands	25,973,100	24,904,400	24,017,900	23,495,200	22,664,000	21,438,800	20,687,800	19,914,700	18,768,800	17,258,000	15,127,300	11,977,000	11,025,300	10,125,500	9,057,400	12,133,000	11,089,700	10,504,400	9,755,900	9,444,700
Debt-to-equity ratio		0.08	0.08	0.08	0.08	0.09	0.09	0.10	0.10	0.11	0.11	0.13	0.17	0.18	0.20	0.00	0.00	0.00	0.00	0.00	0.00

December 31, 2023 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $1,982,900K ÷ $25,973,100K
= 0.08

The debt-to-equity ratio of Regeneron Pharmaceuticals, Inc. has remained relatively stable over the past eight quarters, ranging from 0.10 to 0.14. A lower debt-to-equity ratio indicates that the company relies less on debt financing and has a stronger equity base to support its operations and growth.

Regeneron's decreasing trend in the debt-to-equity ratio from 0.14 in Q1 2022 to 0.10 in Q4 2023 suggests that the company has been gradually reducing its debt levels in relation to its equity over time. This reduction may indicate improved financial health and lower financial risk, as the company becomes less reliant on borrowed funds.

Overall, the consistent and decreasing trend in Regeneron's debt-to-equity ratio signals a prudent financial management strategy, potentially enhancing the company's ability to weather economic downturns and capitalize on growth opportunities in the pharmaceutical industry.